Stankova Jitka, Carret Anne-Sophie, Moore Dorothy, McCusker Christine, Mitchell David, Davis Michael, Mazer Bruce, Jabado Nada
Division of Hematology and Oncology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada.
Pediatr Transplant. 2007 Mar;11(2):209-13. doi: 10.1111/j.1399-3046.2006.00607.x.
We report the case of an infant with severe combined immunodeficiency who was presented with PIV3 infection. Aerosolized ribavirin was administered for 10 months until the child gained a functional immune system through an allogeneic hematopoietic stem cell transplant and cleared PIV3 infection. No adverse effect was observed in the child and in healthcare personnel, with a follow-up of three years. Despite the burden of aerosolized administration, early and prolonged administration of aerosolized ribavirin was feasible, well tolerated, and safe for the patient and the caregivers. This is a case report and no definite conclusions can be drawn. However, our experience suggests that prolonged aerosolized ribavirin administration should be considered for the treatment of PIV3 infection in the context of primary immunodeficiency, where there is no currently available alternative treatment, until a functional immune system is gained.
我们报告了一例患有严重联合免疫缺陷的婴儿感染副流感病毒3型（PIV3）的病例。雾化利巴韦林给药10个月，直至患儿通过异基因造血干细胞移植获得功能性免疫系统并清除PIV3感染。在三年的随访中，未观察到患儿及医护人员出现不良反应。尽管雾化给药有负担，但早期和长期雾化利巴韦林给药对患者和护理人员而言是可行的、耐受性良好且安全的。这是一篇病例报告，无法得出明确结论。然而，我们的经验表明，在原发性免疫缺陷且目前没有其他可用替代治疗的情况下，在获得功能性免疫系统之前，应考虑长期雾化利巴韦林给药来治疗PIV3感染。
